HALOZYME THERAPEUTICS, INC. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2011 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Halozyme Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2011 to Q4 2023.
  • Halozyme Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $2.59M, a 266% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $2.59M +$1.88M +266% Dec 31, 2023 10-K 2024-02-20
Q4 2022 $707K +$207K +41.4% Dec 31, 2022 10-K 2024-02-20
Q4 2021 $500K -$199M -99.8% Dec 31, 2021 10-K 2023-02-21
Q4 2020 $200M +$44.7M +28.8% Dec 31, 2020 10-K 2022-02-22
Q4 2019 $155M +$8.15M +5.54% Dec 31, 2019 10-K 2021-02-23
Q4 2018 $147M +$20.8M +16.5% Dec 31, 2018 10-K 2020-02-24
Q4 2017 $126M -$77.2M -38% Dec 31, 2017 10-K 2019-02-21
Q4 2016 $203M +$20.9M +11.4% Dec 31, 2016 10-K 2018-02-20
Q4 2015 $183M +$3.54M +1.98% Dec 31, 2015 10-K 2017-02-28
Q4 2014 $179M +$17M +10.5% Dec 31, 2014 10-K 2016-02-29
Q4 2013 $162M +$33.5M +26.1% Dec 31, 2013 10-K 2015-03-02
Q4 2012 $128M +$21M +19.5% Dec 31, 2012 10-K 2014-02-28
Q4 2011 $107M Dec 31, 2011 10-K 2013-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.